MedTrace Logo

Revatio Portal-Pulmonary Arterial Hypertension Trial

NCT01517854 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-09-27

No results posted yet for this study

Summary

The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension. Specifically the investigators will evaluate the potential efficacy and safety of sildenafil (Revatio) in a 16 week blinded, multicentre study.

Conditions

  • Portopulmonary Hypertension

Interventions

DRUG

Sildenafil

20 mg Revatio (sildenafil citrate) three times a day

DRUG

Placebo

Placebo identical to Revatio (sildenafil citrate) three times a day

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • John T Granton · University Health Network, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-14
Primary Completion
2017-10-30
Completion
2019-05-14

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01517854 on ClinicalTrials.gov